Knight Therapeutics Inc. (GUD) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. My name is Vanessa, and I will be your operator today. Welcome to Knight Therapeutics' first quarter 2026 results conference call. Before turning the call over to Samira Sakia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you that questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to ir at knighttx.com or via phone at 514-484-4483. I would like to remind everyone that this call is being recorded today, May 7, 2026. I would now like to turn the meeting over to your host for today's call, Samira Sakia. Please go ahead. Thank you, Vanessa. Good morning, everyone, and welcome to Knight Therapeutics' first quarter 2026 conference call. I'm joined on today's call with Amal Khoury, our Chief Business Officer, and Arvind Uchina, our Chief Financial Officer. I'm excited to announce that in the first quarter of 2026, we reported record revenues and record adjusted EBITDA. Our revenues were $148 million,...